Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  Moja, Lorenzo ^a   Lucenteforte, Ersilia ^b   Kwag, Koren H ^a   Bertele, Vittorio ^c   Campomori, Annalisa ^d   Chakravarthy, Usha ^e   D'Amico, Roberto ^f   Dickersin, Kay ^g   Kodjikian, Laurent ^h   Lindsley, Kristina ^g   Loke, Yoon ⁱ   Maguire, Maureen ^j   Martin, Daniel F ^k   Mugelli, Alessandro ^b   Mühlbauer, Bernd ^l   Püntmann, Isabel ^l   Reeves, Barnaby ^m   Rogers, Chris ^m   Schmucker, Christine ⁿ   Subramanian, Manju L ^o   Virgili, Gianni ^b   more..

^a IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d Provincial Agency for Health Services of the Autonomous Province of Trento   (Italy)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h CROIX ROUSSE HOSPITAL   (France)

ⁱ UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

^l KLINIKUM BREMEN MITTE   (Germany)

^m UNIVERSITY OF BRISTOL   (United Kingdom)

ⁿ UNIVERSITY OF FREIBURG   (Germany)

^o BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HUMAN; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; PRIORITY JOURNAL; REMISSION; RETINA NEOVASCULARIZATION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ALL CAUSE MORTALITY; ARTERY THROMBOSIS; BLEEDING; COMPARATIVE EFFECTIVENESS; CONGESTIVE HEART FAILURE; DRUG WITHDRAWAL; HYPERTENSION; INTERVENTION STUDY; OUTCOME ASSESSMENT; VEIN THROMBOSIS; AGED; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; META ANALYSIS; MIDDLE AGED; MORTALITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MIDDLE AGED; RANIBIZUMAB; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84911381185     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011230.pub2     Document Type: Review

References (72)

1. Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian Journal of Ophthalmology 2011;59(3):191-6.
2. Schauwvlieghe A-SM, Dijkman G, Hooymans JM, Verbraak FD, Dijkgraaf MG, Peto T, et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science 2014;55:ARVO E-Abstract 870.
3. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119(7):1388-98.
4. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2011;364(20):1897-908.
5. Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, Decullier E, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013;120(11):2300-9.
6. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382(9900):1258-67.
7. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119(7):1399-411.
8. Berg K. Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference-cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014).
9. Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, Egger S, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. British Journal of Ophthalmology 2013;97(3):266-71.
10. Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye 2010;24(11):1708-15.
11. NCT00559715. Prevention of vision loss in patients with age-related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014).
12. Akl EA, Johnston BC, Alonso-Coello P, Neumann I, Ebrahim S, Briel M, et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One 2013;8(2):e57132.
13. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. British Journal of Ophthalmology 2014 July 7 [Epub ahead of print].
14. Bassler D, Montori VM, Briel M, Glasziou P, Walter SD, Ramsay T, et al. Reflections on meta-analyses involving trials stopped early for benefit: is there a problem and if so, what is it?. Statistical Methods in Medical Research 2013;22(2):159-68.
15. Bosco JL, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. Journal of Clinical Epidemiology 2010;63(1):64-74.
16. Braithwaite T, Nanji AA, Lindsley K, Greenberg PB. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD007325.pub3]
17. Campbell RJ, Gill SS, Bronskill SE, Paterson JM, Whitehead M, Bell CM. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ 2012;345:e4203.
18. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119(7):1399-411.
19. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382(9900):1258-67.
20. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs 2008;68(8):1029-36.
21. Cortes J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Annals of Oncology 2012;23(5):1130-7.
22. Cruess AF, Giacomantonio N. Cardiac issues of noncardiac drugs: the rising story of avastin in age-related macular degeneration. Ophthalmologica 2014;231(2):75-9.
23. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Archives of Ophthalmology 2010;128(10):1273-9.
24. electronic Medicines Compendium (eMC). Avastin 25mg/ml concentrate for solution for infusion. www.medicines.org.uk/emc/medicine/15748 (accessed 31 July 2014).
25. Esarey J, Danneman N. A quantitative method for substantive robustness assessment. jee3.web.rice.edu/riskstats.pdf (accessed 20 August 2014).
26. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26(8):859-70.
27. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Archives of Ophthalmology 1984;102(11):1640-42.
28. French DD, Margo CE. Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study. Retina 2011;31(6):1036-42.
29. Green WR, Enger C. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology 1993;100(10):1519-35.
30. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
31. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
32. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence-imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93.
33. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158-72.
34. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. The Lancet. Oncology. 2009;10(6):559-68.
35. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
36. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at www.cochrane-handbook.org.
37. Horsley W. NHS North East Treatment Advisory Group. Bevacizumab (Avastin®)in the management of neovascular age-related macular degeneration. www.netag.nhs.uk/files/appraisal-reports/Bevacizumab%20-Avastin-%20AMD%20-%20NETAG%20appraisal%20report%20-July%202011.pdf (accessed 15 August 2014).
38. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Introductory guide MedDRA version 17.0. www.meddra.org/sites/default/files/guidance/file/intguide_17_0_english.pdf (accessed 13 July 2014).
39. Ioannidis JP, Lau J. The impact of high-risk patients on the results of clinical trials. Journal of Clinical Epidemiology 1997;50(10):1089-98.
40. Ioannidis JP, Trikalinos TA. Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. Journal of Clinical Epidemiology 2005;58(6):543-9.
41. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005;294(2):218-28.
42. Kasenda B, von Elm E, You J, Blumle A, Tomonaga Y, Saccilotto R, et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA 2014;311(10):1045-51.
43. Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Molecular Vision 2009;15:2803-12.
44. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. American Journal of Ophthalmology 2008;146(4):508-12.
45. LeLorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. New England Journal of Medicine 1997;337(8):536-42.
46. Lim LS, Cheung CM, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents-should ophthalmologists be concerned?. American Journal of Ophthalmology 2011;152(3):329-31.
47. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet 2012;379(9827):5-11.
48. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26(3):257-61.
49. Manzoli L, Flacco ME, D'Addario M, Capasso L, De Vito C, Marzuillo C, et al. Non-publication and delayed publication of randomized trials on vaccines: survey. BMJ 2014;348:g3058.
50. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119(7):1388-98.
51. Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye 2011;25(6):661-72.
52. Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 2013;120(1):106-14.
53. National Cancer Institute. Cancer Therapeutics Evaluation Program. Common Toxicity Criteria for Adverse Events. 3rd Edition. Bethesda, MD: National Cancer Institute, 2003.
54. Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. British Journal of Ophthalmology 2012;96(5):752-6.
55. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305(5):487-94.
56. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
57. Robins J, Breslow N, Greenland S. Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics 1986;42(2):311-23.
58. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opinion on Drug Safety 2006;5(4):553-66.
59. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Statistical Methods in Medical Research 2008;17(3):279-301.
60. Schmucker C, Ehlken C, Hansen LL, Gerd A, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Current Opinion in Ophthalmology 2010;21(3):218-26.
61. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 2012;7:e42701.
62. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009;181(11):787-96.
63. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3]
64. Stergiou PK, Symeonidis C, Dimitrakos SA. Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization. Acta Ophthalmologica 2011;89(3):218-21.
65. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at www.cochrane-handbook.org.
66. Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monocolonal antibodies: a systematic review and meta-analysis. JAMA Ophthalmology 2014 July 24 [Epub ahead of print].
67. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Technical Bulletin 1999;8:1-48.
68. Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macula degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global Health 2014;2(2):e106-16.
69. Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. Journal of the American Society of Nephrology 2010;21(8):1381-9.
70. Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Investigative Ophthalmology and Visual Science 2013;54(3):1616-24.
71. Zhang XY, Guo XF, Zhang SD, He JN, Sun CY, Zou Y, et al. Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis. International Journal of Ophthalmology 2014;7(2):355-64.
72. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD011230]